Investors Overview

Press Release

View printer-friendly version

BD Announces Results for 2019 First Fiscal Quarter; Reaffirms Fiscal 2019 Guidance

- As reported, revenues of $4.160 billion increased 35.1 percent.
- On a comparable, currency-neutral basis, revenues increased 5.2 percent.
- As reported, diluted earnings per share of $2.05 increased 369.7 percent.
- As adjusted, diluted earnings per share of $2.70 increased 8.9 percent, or 14.9 percent on a currency-neutral basis.
- The company reaffirms its full fiscal year 2019 revenue and adjusted diluted earnings per share guidance.

FRANKLIN LAKES, N.J., Feb. 5, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.160 billion for the first fiscal quarter ended December 31, 2018.  This represents an increase of 35.1 percent from the prior-year period, which is primarily due to the acquisition of C. R. Bard.  On a comparable, currency-neutral basis, revenues increased 5.2 percent over the prior-year period.

"We are very pleased with our strong start to fiscal year 2019. As noted in our pre-announcement, results were better than expected across all three segments," said Vincent A. Forlenza, Chairman and CEO.  "It is evident that the combination of BD and C. R. Bard is delivering value to customers, patients and shareholders around the world."

First Quarter Fiscal 2019 Operating Results
As reported, diluted earnings per share for the first quarter were $2.05, compared with $(0.76) in the prior-year period.  This represents an increase of 369.7 percent and is primarily due to the gain on the sale of the Advanced Bioprocessing business, and net expense related to U.S. tax reform in the prior-year period.  Adjusted diluted earnings per share were $2.70, compared with $2.48 in the prior-year period.  This represents an increase in adjusted diluted earnings per share of 8.9 percent, or 14.9 percent on a currency-neutral basis.

Segment Results
In the BD Medical segment, as reported, worldwide revenues for the quarter of $2.135 billion increased 15.3 percent from the prior-year period, primarily due to the acquisition of C. R. Bard.  On a comparable, currency-neutral basis, BD Medical revenues increased 5.2 percent over the prior-year period.  The segment's results were driven by strong performance in the Medication Management Solutions and Pharmaceutical Systems units.

In the BD Life Sciences segment, as reported, worldwide revenues for the quarter were $1.056 billion.  This represents an increase of 1.0 percent over the prior-year period.  On a comparable, currency-neutral basis that excludes the revenues associated with the divested Advanced Bioprocessing business, BD Life Sciences revenues of $1.047 billion increased 4.7 percent over the prior-year period.  Revenue growth was primarily driven by strong performance in the Preanalytical Systems unit.

In the BD Interventional segment, as reported, worldwide revenues for the quarter were $0.970 billion.  On a comparable, currency-neutral basis, revenues increased 5.7 percent over the prior-year period.  The segment's results reflect strong performance in the Surgery and Urology and Critical Care units.  Growth in the Peripheral Intervention unit reflects a tough comparison to the prior-year period.

Geographic Results
As reported, first quarter revenues in the U.S. of $2.387 billion increased 44.1 percent from the prior-year period, primarily due to the acquisition of C. R. Bard.  On a comparable basis, U.S. revenues increased 6.0 percent over the prior-year period.  Growth in the U.S. was driven by strong performance from all three segments.

As reported, revenues outside of the U.S. of $1.773 billion increased 24.6 percent from the prior-year period, primarily due to the acquisition of C. R. Bard.  On a comparable, currency-neutral basis, revenues outside of the U.S. increased 4.1 percent over the prior-year period.  International revenue growth was driven by strong performance in China and the rest of Asia, as well as Latin America.

Fiscal 2019 Outlook for Full Year
The company reaffirms previously issued fiscal year 2019 revenue and adjusted diluted earnings per share guidance.

As reported, the company expects full fiscal year 2019 revenues to increase 8.5 to 9.5 percent, primarily due to the C. R. Bard acquisition.  The company estimates full fiscal year 2019 revenues will increase 5.0 to 6.0 percent on a comparable, currency-neutral basis.

The company expects adjusted diluted earnings per share to be between $12.05 and $12.15, resulting in growth of approximately 13.0 to 14.0 percent on a currency-neutral basis.  This represents growth of approximately 10.0 percent, including the estimated unfavorable impact of foreign currency, over fiscal 2018 adjusted diluted earnings per share of $11.01.

Estimated adjusted diluted earnings per share for fiscal 2019 excludes potential charges or gains that may be recorded during the fiscal year, such as, among other things, the non-cash amortization of intangible assets, acquisition-related charges, and certain tax matters.  BD does not attempt to provide reconciliations of forward-looking non-GAAP earnings guidance to the comparable GAAP measure because the impact and timing of these potential charges or gains is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts.  In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors.  Such items could have a substantial impact on GAAP measures of BD's financial performance.

Conference Call Information
A conference call regarding BD's first quarter results will be broadcast live on BD's website, www.bd.com/investors, along with related slides, at 8:00 a.m. (ET)Tuesday, February 5, 2019.  The conference call will be available for replay on BD's website, www.bd.com/investors, or at 1-800-585-8367 (domestic) and 1-404-537-3406 (international) through the close of business on Tuesday, February 12, 2019, confirmation number 7064558.

Non-GAAP Financial Measures/Financial Tables
This news release contains certain non-GAAP financial measures.  Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables.  Within the attached financial tables presented, certain columns and rows may not add due to the use of rounded numbers.  Percentages and earnings per share amounts presented are calculated from the underlying amounts.

All "comparable" basis revenue growth rates relating to fiscal year 2019 presented throughout this release include, where applicable, the results of C. R. Bard, Inc. ("Bard") in the prior-year period, and also include adjustments for certain items as detailed in the attached tables. Beginning in the second quarter of fiscal year 2018, the Company's organizational structure was based upon three principal business segments: BD Medical ("Medical"), BD Life Sciences ("Life Sciences") and BD Interventional ("Interventional").  The Interventional segment was added upon the Company's completion of its acquisition of Bard, and this new segment includes the majority of Bard's product offerings and certain product offerings that were previously reported in the Medical segment.  Certain of Bard's product offerings are included under the Company's Medical segment, specifically within the new Medication Delivery Solutions unit, which was formerly the Medical segment's Medication and Procedural Solutions unit.  Prior-year amounts have been revised to reflect the movement of certain product offerings that were previously reported in the Medical segment and that are now reported in the Interventional segment, as discussed above.  Current and prior-year adjusted diluted earnings per share results exclude, among other things, the impact of purchase accounting adjustments (including the non-cash amortization of acquisition-related intangible assets); integration, restructuring and transaction costs; and the loss on debt extinguishment.  We also provide these measures on a currency-neutral basis after eliminating the effect of foreign currency translation, where applicable.  We calculate foreign currency-neutral percentages by converting our current-period local currency financial results using the prior period foreign currency exchange rates and comparing these adjusted amounts to our current-period results.  Reconciliations of these amounts to the most directly comparable GAAP measures are included in the tables at the end of this release.

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com.

***

This press release, including the section entitled "Fiscal 2019 Outlook for Full Year", contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues and earnings per share.  All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties.  Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement.  With respect to forward-looking statements contained herein, a number of factors could cause actual results to vary materially.  These factors include, but are not limited to: risks relating to the integration of the C.R. Bard operations, products and employees into BD and the possibility that the anticipated synergies and other benefits of the proposed acquisition will not be realized or will not be realized within the expected timeframe; new or changing laws and regulations impacting our business (including the imposition of tariffs or changes in laws impacting international trade) or changes in enforcement practices with respect to such laws; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; legislative or regulatory changes to the U.S. healthcare system, potential cuts in governmental healthcare spending or measures to contain healthcare costs, each of which could result in reduced demand for our products or downward pricing pressure; changes in interest or foreign currency exchange rates; adverse changes in regional, national or foreign economic conditions, particularly in emerging markets, including any impact on our ability to access credit markets and finance our operations, the demand for our products and services, utilization rates or otherwise, or our suppliers' ability to provide products needed for our operations;  our ability to successfully integrate any businesses we acquire; the adverse impact of cyber-attacks on our information systems or products; competitive factors including technological advances and new products introduced by competitors; interruptions in our supply chain or manufacturing processes; pricing and market pressures; difficulties inherent in product development, delays in product introductions and uncertainty of market acceptance of new products; adverse changes in geopolitical conditions; increases in energy costs and their effect on, among other things, the cost of producing BD's products; product efficacy or safety concerns resulting in product recalls or actions being taken by the FDA or other regulators; uncertainties of litigation (as described in BD's filings with the Securities and Exchange Commission); future healthcare reform outside the U.S., including changes in government pricing and reimbursement policies or other cost containment reforms; and issuance of new or revised accounting standards, as well as other factors discussed in BD's filings with the Securities and Exchange Commission.  We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

Contact:
Monique N. Dolecki, Investor Relations - 201-847-5378
Kristen Cardillo, Corporate Communications - 201-847-5657

 

BECTON DICKINSON AND COMPANY

   

CONSOLIDATED INCOME STATEMENTS

   

(Unaudited; Amounts in millions, except share and per share data)

     
   

Three Months Ended December 31,

   

2018

 

2017

 

% Change

REVENUES

 

$

4,160

   

$

3,080

   

35.1

 
             

Cost of products sold

 

2,187

   

1,527

   

43.2

 

Selling and administrative expense

 

1,073

   

773

   

38.9

 

Research and development expense

 

258

   

191

   

34.8

 

Acquisitions and other restructurings

 

91

   

354

   

(74.4)

 

Other operating income, net

 

(335)

   

   

100.0

 

TOTAL OPERATING COSTS AND EXPENSES

 

3,273

   

2,845

   

15.1

 

OPERATING INCOME

 

888

   

235

   

277.3

 
             

Interest expense

 

(171)

   

(158)

   

7.7

 

Interest income, net

 

(12)

   

44

   

(128.3)

 

Other income (expense), net

 

10

   

(16)

   

163.6

 

INCOME BEFORE INCOME TAXES

 

714

   

105

   

580.7

 

Income tax provision

 

115

   

241

   

(52.4)

 

NET INCOME (LOSS)

 

599

   

(136)

   

539.3

 

Preferred stock dividends

 

(38)

   

(38)

   

 

NET INCOME (LOSS) APPLICABLE TO COMMON SHAREHOLDERS

 

$

562

   

$

(174)

   

422.1

 
             

EARNINGS PER SHARE

           

Basic Earnings (Loss) per Share

 

$

2.09

   

$

(0.76)

   

375.0

 

Diluted Earnings (Loss) per Share

 

$

2.05

   

$

(0.76)

   

369.7

 
             

AVERAGE SHARES OUTSTANDING (in thousands)

           

Basic

 

269,035

 

230,038

   

Diluted

 

274,256

 

230,038

   

 

 

BECTON DICKINSON AND COMPANY

   

CONDENSED CONSOLIDATED BALANCE SHEETS

   

(Amounts in millions)

   
     
   

December 31, 2018

 

September 30, 2018

   

(Unaudited)

   

ASSETS

       

Cash and equivalents

 

$

943

   

$

1,140

 

Restricted cash

 

98

   

96

 

Short-term investments

 

5

   

17

 

Trade receivables, net

 

2,216

   

2,319

 

Inventories

 

2,522

   

2,451

 

Assets held for sale

 

   

137

 

Prepaid expenses and other

 

1,157

   

1,251

 

TOTAL CURRENT ASSETS

 

6,941

   

7,411

 

Property, plant and equipment, net

 

5,362

   

5,375

 

Goodwill and other intangibles, net

 

39,567

   

40,041

 

Other Assets

 

1,062

   

1,078

 

TOTAL ASSETS

 

$

52,932

   

$

53,904

 

LIABILITIES AND SHAREHOLDERS' EQUITY

       

Short-term debt

 

$

3,254

   

$

2,601

 

Other current liabilities

 

3,891

   

4,615

 

Long-term debt

 

17,817

   

18,894

 

Long-term employee benefit obligations

 

805

   

1,056

 

Deferred income taxes and other

 

5,762

   

5,743

 

Shareholders' equity

 

21,404

   

20,994

 

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY

 

$

52,932

   

$

53,904

 

 

 

BECTON DICKINSON AND COMPANY

   

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited; Amounts in millions)

   
     
   

Three Months Ended December 31,

   

2018

 

2017

OPERATING ACTIVITIES

       

Net income (loss)

 

$

599

   

$

(136)

 

Depreciation and amortization

 

563

   

291

 

Change in operating assets and liabilities and other, net

 

(918)

   

166

 

NET CASH PROVIDED BY OPERATING ACTIVITIES

 

245

   

320

 

INVESTING ACTIVITIES

       

Capital expenditures

 

(167)

   

(178)

 

Acquisitions of businesses, net of cash acquired

 

   

(14,900)

 

Proceeds from divestitures, net

 

476

   

 

Other, net

 

(9)

   

(125)

 

NET CASH PROVIDED BY (USED FOR) INVESTING ACTIVITIES

 

299

   

(15,203)

 

FINANCING ACTIVITIES

       

Change in credit facility borrowings

 

50

   

 

Proceeds from long-term debt and term loans

 

   

2,250

 

Payments of debt and term loans

 

(453)

   

 

Dividends paid

 

(245)

   

(210)

 

Other, net

 

(86)

   

(101)

 

NET CASH (USED FOR) PROVIDED BY FINANCING ACTIVITIES

 

(734)

   

1,938

 

Effect of exchange rate changes on cash and equivalents and restricted cash

 

(5)

   

2

 

NET DECREASE IN CASH AND EQUIVALENTS AND RESTRICTED CASH

 

(195)

   

(12,943)

 

OPENING CASH AND EQUIVALENTS AND RESTRICTED CASH

 

1,236

   

14,179

 

CLOSING CASH AND EQUIVALENTS AND RESTRICTED CASH

 

$

1,042

   

$

1,236

 

 

 

BECTON DICKINSON AND COMPANY

   

SUPPLEMENTAL REVENUE INFORMATION

   

REVENUES BY BUSINESS SEGMENTS AND UNITS - UNITED STATES

Three Months Ended December 31,

   

(Unaudited; Amounts in millions)

   
     
   

A

 

B

 

C=(A-B)/B

   

2018

 

2017

 

% Change

BD MEDICAL

           

Medication Delivery Solutions (a)

 

$

520

   

$

370

   

40.5

 

Medication Management Solutions

 

506

   

471

   

7.5

 

Diabetes Care

 

145

   

146

   

(0.5)

 

Pharmaceutical Systems

 

68

   

54

   

26.8

 

TOTAL

 

$

1,239

   

$

1,040

   

19.1

 
             

BD LIFE SCIENCES

           

Preanalytical Systems

 

$

201

   

$

184

   

8.8

 

Diagnostic Systems

 

175

   

167

   

5.2

 

Biosciences

 

108

   

108

   

(0.2)

 

TOTAL

 

$

484

   

$

459

   

5.4

 
             

BD INTERVENTIONAL

           

Surgery (a)

 

$

275

   

$

152

   

NM

 

Peripheral Intervention (a)

 

191

   

5

   

NM

 

Urology and Critical Care

 

197

   

   

NM

 

TOTAL

 

$

664

   

$

157

   

NM

 
             

TOTAL UNITED STATES

 

$

2,387

   

$

1,657

   

44.1

 
   

(a)  

The presentation of prior-period amounts reflects a reclassification of $157 million associated with the movement, effective on January 1, 2018, of certain product offerings from the Medical segment to the Interventional segment.

 

 

BECTON DICKINSON AND COMPANY

   

SUPPLEMENTAL REVENUE INFORMATION

 

REVENUES BY BUSINESS SEGMENTS AND UNITS - INTERNATIONAL

Three Months Ended December 31, (continued)

 

(Unaudited; Amounts in millions)

   
     
               

D=(A-B)/B

 

E=(A-B-C)/B

   

A

 

B

 

C

 

% Change

   

2018

 

2017

 

FX Impact

 

Reported

 

FXN

BD MEDICAL

                   

Medication Delivery Solutions (a)

 

$

438

   

$

372

   

$

(20)

   

17.7

   

23.0

 

Medication Management Solutions

 

118

   

116

   

(3)

   

1.1

   

3.8

 

Diabetes Care

 

129

   

132

   

(5)

   

(2.2)

   

1.5

 

Pharmaceutical Systems

 

212

   

192

   

(4)

   

10.5

   

12.6

 

TOTAL

 

$

896

   

$

811

   

$

(32)

   

10.4

   

14.3

 
                     

BD LIFE SCIENCES

                   

Preanalytical Systems

 

$

192

   

$

191

   

$

(9)

   

0.8

   

5.4

 

Diagnostic Systems

 

207

   

214

   

(7)

   

(3.6)

   

(0.2)

 

Biosciences

 

173

   

181

   

(5)

   

(4.3)

   

(1.6)

 

TOTAL

 

$

572

   

$

586

   

$

(21)

   

(2.4)

   

1.2

 
                     

BD INTERVENTIONAL

                   

Surgery (a)

 

$

73

   

$

25

   

$

(2)

   

NM

   

NM

 

Peripheral Intervention (a)

 

145

   

1

   

(5)

   

NM

   

NM

 

Urology and Critical Care

 

88

   

   

(2)

   

NM

   

NM

 

TOTAL

 

$

306

   

$

26

   

$

(9)

   

NM

   

NM

 
                     

TOTAL INTERNATIONAL

 

$

1,773

   

$

1,423

   

$

(62)

   

24.6

   

28.9

 
   

(a)  

The presentation of prior-period amounts reflects a reclassification of $26 million associated with the movement, effective on January 1, 2018, of certain product offerings from the Medical segment to the Interventional segment.

 

 

BECTON DICKINSON AND COMPANY

   

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS - TOTAL

Three Months Ended December 31, (continued)

(Unaudited; Amounts in millions)

   
     
               

D=(A-B)/B

 

E=(A-B-C)/B

   

A

 

B

 

C

 

% Change

   

2018

 

2017

 

FX Impact

 

Reported

 

FXN

BD MEDICAL

                   

Medication Delivery Solutions (a)

 

$

958

   

$

742

   

$

(20)

   

29.1

   

31.7

 

Medication Management Solutions

 

624

   

587

   

(3)

   

6.2

   

6.7

 

Diabetes Care

 

274

   

277

   

(5)

   

(1.3)

   

0.5

 

Pharmaceutical Systems

 

280

   

245

   

(4)

   

14.0

   

15.7

 

TOTAL

 

$

2,135

   

$

1,852

   

$

(32)

   

15.3

   

17.0

 
                     

BD LIFE SCIENCES

                   

Preanalytical Systems

 

$

393

   

$

375

   

$

(9)

   

4.7

   

7.1

 

Diagnostic Systems

 

382

   

381

   

(7)

   

0.2

   

2.1

 

Biosciences

 

281

   

289

   

(5)

   

(2.8)

   

(1.1)

 

TOTAL

 

$

1,056

   

$

1,045

   

$

(21)

   

1.0

   

3.0

 
                     

BD INTERVENTIONAL

                   

Surgery (a)

 

$

348

   

$

177

   

$

(2)

   

NM

   

NM

 

Peripheral Intervention (a)

 

337

   

6

   

(5)

   

NM

   

NM

 

Urology and Critical Care

 

285

   

   

(2)

   

NM

   

NM

 

TOTAL

 

$

970

   

$

183

   

$

(9)

   

NM

   

NM

 
                     

TOTAL REVENUES

 

$

4,160

   

$

3,080

   

$

(62)

   

35.1

   

37.1

 
   

(a)     

The presentation of prior-period amounts reflects a reclassification of $183 million associated with the movement, effective on January 1, 2018, of certain product offerings from the Medical segment to the Interventional segment.

 

 

BECTON DICKINSON AND COMPANY

                                     

SUPPLEMENTAL INFORMATION

                                     

RECONCILIATION OF REPORTED REVENUE CHANGE TO COMPARABLE REVENUE CHANGE - UNITED STATES

                   

Three Months Ended December 31,

                                     

(Unaudited; Amounts in millions)

                                     
                                         
   

A

 

B

 

C=A+B

   

D

 

E

 

F

 

G

 

H=D+E+F+G

   

I=(C-H)/H

   

BD Reported

 

Divestiture Adjustments (a)

 

Comparable

   

BD Reported (b)

 

Bard Q1 (c)

 

Intercompany Adjustment (d)

 

Divestiture Adjustments (a)

 

Comparable

   

Comparable % Change

   

2018

   

2018

   

2017

 

2017

     

2017

   

BD MEDICAL

                                       

Medication Delivery Solutions (b)

 

$

520

   

$

   

$

520

     

$

370

   

$

145

   

$

(3)

   

$

   

$

512

     

1.6

 

Medication Management Solutions

 

506

   

   

506

     

471

   

   

   

   

471

     

7.5

 

Diabetes Care

 

145

   

   

145

     

146

   

   

   

   

146

     

(0.5)

 

Pharmaceutical Systems

 

68

   

   

68

     

54

   

   

   

   

54

     

26.8

 

TOTAL

 

$

1,239

   

$

   

$

1,239

     

$

1,040

   

$

145

   

$

(3)

   

$

   

$

1,182

     

4.8

 
                                         

BD LIFE SCIENCES

                                       

Preanalytical Systems

 

$

201

   

$

   

$

201

     

$

184

   

$

   

$

   

$

   

$

184

     

8.8

 

Diagnostic Systems

 

175

   

   

175

     

167

   

   

   

   

167

     

5.2

 

Biosciences

 

108

   

(4)

   

105

     

108

   

   

   

(10)

   

98

     

6.4

 

TOTAL

 

$

484

   

$

(4)

   

$

480

     

$

459

   

$

   

$

   

$

(10)

   

$

449

     

6.9

 
                                         

BD INTERVENTIONAL

                                       

Surgery (b)

 

$

275

   

$

   

$

275

     

$

152

   

$

105

   

$

   

$

(10)

   

$

247

     

11.3

 

Peripheral Intervention (b)

 

191

   

   

191

     

5

   

188

   

   

   

193

     

(0.6)

 

Urology and Critical Care

 

197

   

   

197

     

   

177

   

   

   

177

     

11.5

 

TOTAL

 

$

664

   

$

   

$

664

     

$

157

   

$

470

   

$

   

$

(10)

   

$

617

     

7.6

 
                                         

TOTAL UNITED STATES

 

$

2,387

   

$

(4)

   

$

2,383

     

$

1,657

   

$

614

   

$

(3)

   

$

(20)

   

$

2,248

     

6.0

 
   

(a)     

The amounts for the quarters ended December 31, 2018 and 2017 include adjustments for BD's divestiture of its Advanced Bioprocessing business.  The amounts for the quarter ended December 31, 2017 also include adjustments for BD's divestitures of its soft tissue core needle biopsy product line and Bard's divestiture of its Aspira® product line.

(b)    

Reflects a reclassification of $157 million associated with the movement, effective on January 1, 2018, of certain product offerings from the Medical segment to the Interventional segment.

(c)     

Amounts represent revenues for the quarter ended December 31, 2017.  BD reported a Gore royalty amount, which was previously reported as revenues by Bard, as non-operating income in the current-year period.

(d)    

Represents the elimination of revenues from the Medication Delivery Solutions unit which BD previously recognized from Bard as third-party revenues and that would be treated as intercompany revenues in the current-year period.

 

 

BECTON DICKINSON AND COMPANY

                                     

SUPPLEMENTAL INFORMATION

                                       

RECONCILIATION OF REPORTED REVENUE CHANGE TO COMPARABLE REVENUE CHANGE - INTERNATIONAL

       

Three Months Ended December 31, (continued)

                                     

(Unaudited; Amounts in millions)

                                       
                                         
   

A

 

B

 

C=A+B

   

D

 

E

 

F

 

G=D+E+F

   

H

 

I=(C-G-H)/G

   

BD Reported

 

Divestiture Adjustments (a)

 

Comparable

   

BD Reported (b)

 

Bard Q1 (c)

 

Divestiture Adjustments (a)

 

Comparable

   

FX Impact (d)

 

FXN % Change

   

2018

   

2018

   

2017

 

2017

   

2017

     

BD MEDICAL

                                       

Medication Delivery Solutions (b)

 

$

438

   

$

   

$

438

     

$

372

   

$

68

   

$

   

$

440

     

$

(22)

   

4.3

 

Medication Management Solutions

 

118

   

   

118

     

116

   

   

   

116

     

(3)

   

3.8

 

Diabetes Care

 

129

   

   

129

     

132

   

   

   

132

     

(5)

   

1.8

 

Pharmaceutical Systems

 

212

   

   

212

     

192

   

   

   

192

     

(4)

   

12.6

 

TOTAL

 

$

896

   

$

   

$

896

     

$

811

   

$

68

   

$

   

$

880

     

$

(34)

   

5.7

 
                                         

BD LIFE SCIENCES

                                       

Preanalytical Systems

 

$

192

   

$

   

$

192

     

$

191

   

$

   

$

   

$

191

     

$

(11)

   

6.3

 

Diagnostic Systems

 

207

   

   

207

     

214

   

   

   

214

     

(9)

   

0.8

 

Biosciences

 

173

   

(5)

   

168

     

181

   

   

(10)

   

171

     

(6)

   

2.0

 

TOTAL

 

$

572

   

$

(5)

   

$

567

     

$

586

   

$

   

$

(10)

   

$

576

     

$

(26)

   

3.0

 
                                         

BD INTERVENTIONAL

                                       

Surgery (b)

 

$

73

   

$

   

$

73

     

$

25

   

$

49

   

$

(2)

   

$

71

     

$

(2)

   

5.4

 

Peripheral Intervention (b)

 

145

   

   

145

     

1

   

146

   

   

147

     

(5)

   

2.2

 

Urology and Critical Care

 

88

   

   

88

     

   

90

   

   

90

     

(2)

   

(1.0)

 

TOTAL

 

$

306

   

$

   

$

306

     

$

26

   

$

285

   

$

(2)

   

$

309

     

$

(9)

   

2.0

 
                                         

TOTAL INTERNATIONAL

 

$

1,773

   

$

(5)

   

$

1,768

     

$

1,423

   

$

353

   

$

(12)

   

$

1,764

     

$

(69)

   

4.1

 
   

(a)     

The amounts for the quarters ended December 31, 2018 and 2017 include adjustments for BD's divestiture of its Advanced Bioprocessing business.  The amounts for the quarter ended December 31, 2017 also include adjustments for BD's divestitures of its soft tissue core needle biopsy product line and Bard's divestiture of its Aspira® product line.

(b)    

Reflects a reclassification of $26 million associated with the movement, effective on January 1, 2018, of certain product offerings from the Medical segment to the Interventional segment.

(c)     

Amounts represent revenues for the quarter ended December 31, 2017.

(d)    

Under U.S. generally accepted accounting principles and as a result of Argentina's highly inflationary economy, the functional currency of the Company's operations in Argentina was the U.S. dollar for the quarter ended December 31, 2018.  The total foreign currency translation impact above includes $7 million that was calculated by comparing local currency revenues in Argentina for the quarter ended December 31, 2018, translated using the prior-period exchange rate, to the reported U.S. dollar revenues for this same period.

 

 

BECTON DICKINSON AND COMPANY

 

SUPPLEMENTAL INFORMATION

   

RECONCILIATION OF REPORTED REVENUE CHANGE TO COMPARABLE REVENUE CHANGE - TOTAL

Three Months Ended December 31, (continued)

 

(Unaudited; Amounts in millions)

   
     
   

A

 

B

 

C=A+B

   

D

 

E

 

F

 

G

 

H=D+E+F+G

   

I

 

J=(C-H-I)/H

   

BD Reported

 

Divestiture Adjustments (a)

 

Comparable

   

BD Reported (b)

 

Bard Q1 (c)

 

Intercompany Adjustment (d)

 

Divestiture Adjustments (a)

 

Comparable

   

FX Impact (e)

 

FXN % Change

   

2018

   

2018

   

2017

 

2017

     

2017

     

BD MEDICAL

                                           

Medication Delivery Solutions (b)

 

$

958

   

$

   

$

958

     

$

742

   

$

213

   

$

(3)

   

$

   

$

952

     

$

(22)

   

2.9

 

Medication Management Solutions

 

624

   

   

624

     

587

   

   

   

   

587

     

(3)

   

6.7

 

Diabetes Care

 

274

   

   

274

     

277

   

   

   

   

277

     

(5)

   

0.6

 

Pharmaceutical Systems

 

280

   

   

280

     

245

   

   

   

   

245

     

(4)

   

15.7

 

TOTAL

 

$

2,135

   

$

   

$

2,135

     

$

1,852

   

$

213

   

$

(3)

   

$

   

$

2,062

     

$

(34)

   

5.2

 
                                             

BD LIFE SCIENCES

                                           

Preanalytical Systems

 

$

393

   

$

   

$

393

     

$

375

   

$

   

$

   

$

   

$

375

     

$

(11)

   

7.6

 

Diagnostic Systems

 

382

   

   

382

     

381

   

   

   

   

381

     

(9)

   

2.7

 

Biosciences

 

281

   

(9)

   

273

     

289

   

   

   

(20)

   

269

     

(6)

   

3.6

 

TOTAL

 

$

1,056

   

$

(9)